Is biopharma getting better at accelerated approval conversions?
Amid ongoing pressure to reform the FDA’s fast-track pathway, signs emerge that the criticism is being heard.
How Covid failed to derail the FDA
Average US review times match absolute approval numbers in remaining unaffected by the Covid pandemic.
The biggest launches of 2022: a reboot
New Alzheimer’s launches are all but ruled out, so projects from Lilly, Alynlam and Roche top 2022’s biggest hopes.
